Company news
Jiangsu Kanion Pharmaceutical Co. Ltd. Class A (SSE:600557) news
Jiangsu Kanion Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Nov 28, 2024: Announcement on Receiving Notice of Approval for Clinical Trial…
Press releases — page 2
Announcement on Receiving Notice of Approval for Clinical Trial of KYHY2302 Cream
November 27, 2024
Announcement on Resolution of the 14th Extraordinary Meeting of the 8th Board of Directors
November 25, 2024
Announcement on Reply to "Letter of Supervision on Related Party Transactions of Jiangsu Kanion Pharmaceutical Co., Ltd." from SSE and Adjustment of Transaction Plan
November 24, 2024
Announcement on Receiving FDA's Approval for Clinical Trial of KYS202004A Injection
November 8, 2024
Announcement on Resolution of the 13th Meeting of the 8th Board of Directors
November 7, 2024
Announcement on Progress in Repurchasing Shares through Call Auction
November 1, 2024
Report for Q3 2024
October 30, 2024
Announcement on Repurchasing 2% of the Company's Share Capital through Auction and Repurchase Progress
September 13, 2024
Announcement on Receiving Notice of Approval for Clinical Trial of KYS202004A Injection
September 5, 2024
Announcement Obtaining Drug Registration Certificate for Detoxification Granules
August 23, 2024
Announcement on Resolution of the 1st Extraordinary General Meeting in 2024
August 12, 2024
Announcement on Reply to "Letter of Supervision on Related Party Transactions of Jiangsu Kanion Pharmaceutical Co., Ltd." from SSE
August 5, 2024
Announcement on Progress in Repurchasing Shares through Auction
August 1, 2024
Announcement on Repurchasing 1% of the Company's Share Capital through Auction and Repurchase Progress
July 29, 2024